PRESS RELEASE published on 05/07/2026 at 10:11, 1 month 21 days ago Virbac : Declaration of the number of shares and voting rights 04/2026 Declaration of the number of shares and voting rights for VIRBAC on Euronext Paris. Total voting rights: 12,707,056. Total shares: 8,390,660 as of April 30, 2026 Euronext Paris Voting Rights Shares Financial Market VIRBAC
PRESS RELEASE published on 05/07/2026 at 10:11, 1 month 21 days ago Virbac : Déclaration d'actions et de droits de vote 04/2026 Déclaration du nombre total d'actions et de droits de vote pour VIRBAC sur Euronext Paris. Total brut de droits de vote : 12 707 056, Total net : 12 698 020 Euronext Paris Déclaration Droits De Vote Santé Animale VIRBAC
BRIEF published on 04/07/2026 at 11:10, 2 months 21 days ago Virbac : Déclaration sur les droits de vote au 31 mars 2026 Droits De Vote Euronext Actions Finances VIRBAC
BRIEF published on 04/07/2026 at 11:10, 2 months 21 days ago Virbac: Declaration on voting rights as of March 31, 2026 Voting Rights Euronext Actions Finance VIRBAC
PRESS RELEASE published on 04/07/2026 at 11:05, 2 months 21 days ago Virbac : Déclaration d'actions et de droits de votes 03/2026 Déclaration d'actions et de droits de vote pour Virbac, société cotée sur Euronext Paris. Détails sur le nombre total d'actions et de droits de vote. Contact : finances@virbac.com Euronext Paris Déclaration Droits De Vote Santé Animale VIRBAC
PRESS RELEASE published on 03/17/2026 at 19:00, 3 months 10 days ago Virbac: Communiqué de mise à disposition des comptes consolidés au 31 décembre 2025
PRESS RELEASE published on 03/17/2026 at 19:00, 3 months 10 days ago Virbac: Public Release of the Year-End Consolidated Accounts at 31 December 2025
BRIEF published on 12/16/2025 at 09:58, 6 months 12 days ago Virbac acquiert Thyronorm pour le traitement de l'hyperthyroïdie féline Acquisition Santé Animale VIRBAC Hyperthyroïdie Féline Thyronorm
BRIEF published on 12/16/2025 at 09:58, 6 months 12 days ago Virbac Acquires Thyronorm to Combat Feline Hyperthyroidism Veterinary Medicine Animal Health Feline Hyperthyroidism VIRBAC Thyronorm
BRIEF published on 12/16/2025 at 09:58, 6 months 12 days ago Virbac acquiert Thyronorm pour lutter contre l'hyperthyroïdie féline Santé Animale Médecine Vétérinaire VIRBAC Hyperthyroïdie Féline Thyronorm
Published on 06/27/2026 at 16:50, 21 hours 14 minutes ago Redwood AI Announces Definitive Agreement with Quantum.IQ and Expands into Quantum Resistant Cyber Security
Published on 06/27/2026 at 01:40, 1 day 12 hours ago Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 1 day 14 hours ago Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 1 day 15 hours ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 1 day 15 hours ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/27/2026 at 00:05, 1 day 13 hours ago EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 1 day 13 hours ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 1 day 14 hours ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 1 day 14 hours ago EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 1 day 14 hours ago EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE
